Moderna: positive data for an influenza-Covid vaccine
(CercleFinance.com) - Biotech group Moderna reports positive interim results from the Phase I/II trial of its mRNA-1083, an experimental combination vaccine for both influenza and Covid-19.
mRNA-1083 showed strong immunogenicity against influenza and Covid-19, with an acceptable reactogenicity and safety profile, compared to licensed stand-alone vaccines, it said.
Moderna plans to start a Phase III trial of mRNA-1083 in adults over 50 by the end of this year, and is aiming for potential regulatory approval for this combination vaccine in 2025.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
mRNA-1083 showed strong immunogenicity against influenza and Covid-19, with an acceptable reactogenicity and safety profile, compared to licensed stand-alone vaccines, it said.
Moderna plans to start a Phase III trial of mRNA-1083 in adults over 50 by the end of this year, and is aiming for potential regulatory approval for this combination vaccine in 2025.
Copyright (c) 2023 CercleFinance.com. All rights reserved.